StocksRunner logo
mail
search
 
menu
 
Novavax
6.41
0.00%
 
  Overview  
  
  Analysis  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
 
 

NVAX

 

Novavax

$6.41

 
-$0.00 | 0.00%
 
  Overview  
  
  Analysis  
  
     Risks     
  
  Rating  
  
     Chart     
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
  
  Headlines  
 
 
Open
$ 6.51
 
 
MKT CAP
$ 1.04B
 
High
$ 6.58
 
 
VOL
$ 2.97M
 
Low
$ 6.38
 
 
AVG VOL
$ 6.24M
 
 
 

Chart

 
 

7.69

8.13

8.7

12.99

 
 
1year
6month
3month
1month
 
NVAX Latest Headlines +
 
 
 
StocksRunner

Explore our NVAX Stock insights

  • In-Depth Market Analysis and Trends
  • Expert Insights on Market Dynamics
  • Tailored NVAX Stock Strategies
  • Effective Risk Management
 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss
 

Receive our NVAX Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

 
Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

 
Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

 
Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

 
About StocksRunner

Log In

Sign Up

Plans & Pricing

Contact Us

Terms of use

Privacy Policy

 
 
StocksRunner
 
 
StocksRunner
Overview
 
StocksRunner
Trending
 
StocksRunner
Screener
 
StocksRunner
Ideas
 
StocksRunner
Top Rated
 
StocksRunner
Momentum
 
StocksRunner
Earnings
 
 

Recently Viewed

 

NVAX

Novavax

 
 
 

Most Trending

 
 
 
Top Banner
 
  Overview  
  
  Analysis  
  
   Risks   
  
  Rating  
  
  Chart  
  
  Analysts  
  
  Street  
  
  Sentiment  
  
  Earnings  
 
 
 
 
 
 

NVAX

 

Novavax

$6.41

 
-$0.00 | 0.00%
 

 

Chart

 
 

7.69

8.13

8.7

12.99

 
 
1year
6month
3month
1month
 
 
 
 

NVAX Latest Headlines

 
 
 

Trump-Era FDA Appointees Request New Trials For Novavax COVID Vaccine Reportedly Delaying Approval Timeline. The President ) to conduct new clinical trials for its COVID-19 vaccine.The requirement came shortly after FDA Commissioner

 

Tue Apr 29, 2025

 
Activity

Novavax shares fall following WSJ report on FDA trial request.

 

Fri Apr 25, 2025

 
Momentum

Novavaxs COVID-19 Vaccine Nears FDA Full Approval Stock Jumps. ) stock traded higher on Wednesday.In an SEC filing Novavax “.We believe that our Biologics License Application (BLA) is approvable based on conversations with United States Food and Drug Administration (FDA) as of our Prescription Drug User Fee Act date on .”.The company said that it received formal communication from the FDA in the form of an information request for a post-marketing commitment to generate additional clin

 

Wed Apr 23, 2025

 
Activity
Momentum

Novavax shares soar after FDA request raises hope for COVID vaccine approval.

 

Wed Apr 23, 2025

 
Momentum

 
 
 
 
 
StocksRunner

Discover NVAX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of NVAX. We're here to help you make informed investment decisions today.

 

FIND US ON

StocksRunner on Facebook StocksRunner on Twitter StocksRunner on YouTube StocksRunner on stocktwits StocksRunner Rss

 

Receive our NVAX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

 
Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

NVAX Stock trends

NVAX Stock performance

NVAX Stock analysis

NVAX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner ideas

Financial Reports

 
 

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

 
 
StocksRunner logo
 
Post ×
 
0/666
joker